SymbioCellTech Revenue and Competitors
Estimated Revenue & Valuation
- SymbioCellTech's estimated annual revenue is currently $775k per year.
- SymbioCellTech's estimated revenue per employee is $155,000
Employee Data
- SymbioCellTech has 5 Employees.
- SymbioCellTech grew their employee count by -29% last year.
SymbioCellTech's People
Name | Title | Email/Phone |
---|---|---|
1 | Founder & CEO | Reveal Email/Phone |
2 | Chief Scientific Officer | Reveal Email/Phone |
3 | Chief Operating Officer | Reveal Email/Phone |
4 | Scientist | Reveal Email/Phone |
SymbioCellTech Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.8M | 5 | -17% | N/A | N/A |
#2 | $1.4M | 9 | -10% | N/A | N/A |
#3 | $5.9M | 38 | 41% | N/A | N/A |
#4 | $1.1M | 7 | -53% | N/A | N/A |
#5 | $1.6M | 10 | 11% | N/A | N/A |
#6 | $21.2M | 137 | 10% | N/A | N/A |
#7 | $1.6M | 33 | -48% | $17.8M | N/A |
#8 | $1.9M | 12 | 0% | N/A | N/A |
#9 | $3.7M | 24 | 9% | N/A | N/A |
#10 | $0.9M | 6 | 0% | N/A | N/A |
What Is SymbioCellTech?
SymbioCellTech (SCT) is an early stage, university spin out, that has developed stem cell-based technology that achieves euglycemia (glucose control) in Type-1 Diabetes, and will soon be adapted for Type-2 Diabetes. The SCT proprietary Neo-Iset therapy, comprising both pancreatic islet and mesenchymal stem cells, can be administered in a simple out-patient procedure resulting in glucose control identical to that of a normal healthy individual. Backed by rigorous NIH, VA and privately funded research and resultant data, SCT has completed pre-clinical trials and is preparing for FDA submission and approval to begin well-designed, controlled, clinical trials treating humans suffering from Type-1 Diabetes. FDA Investigational New Animal Drug (INAD) approval for diabetic companion animals has been approved and canine clinical trials are ongoing with outstanding results and outcomes.
keywords:N/AN/A
Total Funding
5
Number of Employees
$775k
Revenue (est)
-29%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.8M | 5 | -17% | N/A |
#2 | $0.5M | 5 | -17% | N/A |
#3 | $0.4M | 5 | -17% | N/A |
#4 | $15M | 5 | -37% | N/A |
#5 | $0.4M | 5 | -17% | N/A |